Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 13, 1999

View Archived Issues

AstraZeneca takes an ambitious approach to drug R&D

HIV-VAC's AIDS vaccine progressing in clinical trials in Russia

New class of antidiabetic agents under study at Novo Nordisk

Boehringer Ingelheim assumes full responsibility for continued development of novel antitumor agent

Hypoxanthine derivatives from NeoTherapeutics useful for depression, obesity, etc.

Mallinckrodt's MRI contrast agent approved for marketing in U.S.

ImmunoGen's lead tumor-activated prodrug enters the clinic

"Inactive" pharmaceutical excipient demonstrates potent anti-HSV activity in vitro and in vivo

Ribozyme to form joint venture with Elan for breast cancer therapeutic

Water-soluble mesilate salt form of known antitumor agent prepared at Pfizer

Antiproliferative agents derived from vegetable oil in development at PharmaScience

Medivir investigates new treatments for hepatitis B

A6/cyclophosphamide combination to be studied as antimetastatic therapy

HU-308: a potent and specific agonist at the peripheral cannabinoid receptor

AHP denies rumors of merger talks with P&U

Zambon initiates phase II trial of Sheffield's MSI albuterol

Vion's TAPET administered to first patients intratumorally in phase I trial

HGF gene therapy for acute GVHD: studies in mice

AEterna presents promising phase I data for AE-941 in AMD

KRN-7000-stimulated human cells effective in vitro against melanoma cell lines

Cypress Bioscience and Medexus enter agreement for Prosorba Column in Canada

New chikungunya virus vaccine safe and highly immunogenic in humans

Recombinant HEV vaccine: safety and immunogenicity in monkeys and humans

PPL Therapeutics announces promising preliminary data from AAT deficiency trial

Lorus Therapeutics cleared to initiate clinical trials of GTI-2040

Merck KGaA finalizes Theramex acquisition

Potent new anticonvulsants emerge from China

Versicor achieves milestone in antibacterial collaboration with Novartis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 22, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...